Arsenale Bioyards introduces a platform reversing traditional workflows to optimize yeast-based biomanufacturing, standardizing industrialization to reduce costs and streamline scale-up using AI and precision fermentation. In parallel, Insilico Medicine launches an AI-powered design strategy to develop selective FGFR2/3 inhibitors for precision oncology. Additionally, Unnatural Products collaborates with argenx to create oral macrocyclic peptides targeting immunological diseases using AI-guided compound design, highlighting the increasing convergence of AI with drug development and bioprocess engineering.